AvePoint Announces Expiration and Results of the Offer to Purchase and Consent Solicitation Relating to its Warrants

AvePoint, Inc.
AvePoint, Inc.

In This Article:

JERSEY CITY, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- AvePoint (Nasdaq: AVPT, AVPTW), the global leader in robust data management and data governance, today announced the expiration of its offer to purchase (the “Offer”) all of its outstanding Warrants (as defined below) at a purchase price of $2.50 per Warrant in cash, without interest.

AvePoint’s offer to purchase 17,576,241 publicly traded warrants which were publicly issued and sold as part of the units in the initial public offering of Apex Technology Acquisition Corporation (“Apex”) consummated on September 19, 2019, and which entitle such warrant holders to purchase one share of AvePoint’s common stock, par value $0.0001 per share, at an exercise price of $11.50, subject to certain adjustments (the “Warrants”), expired at 12:00 midnight, Eastern Time, at the end of the day on September 24, 2024 (the “Expiration Date”).

AvePoint has been advised that, as of the Expiration Date, 1,596,314 Warrants had been validly tendered and not validly withdrawn, representing approximately 9.1% of the outstanding Warrants. The Company has accepted all validly tendered Warrants for purchase and expects to settle such purchase promptly. Pursuant to the terms of the Offer, holders of Warrants that were validly tendered and not validly withdrawn prior to the Expiration Date will receive $2.50 for each Warrant tendered. The Company expects to pay an aggregate of approximately $4.0 million in cash to purchase the validly tendered Warrants.

AvePoint also solicited consents (the “Consent Solicitation”) to amend the Warrant Agreement, dated September 16, 2019, by and between Apex and Continental Stock Transfer & Trust Company (the “Warrant Agreement”), which governs all of the Warrants, to permit AvePoint to redeem each outstanding Warrant not tendered in the Offer for $2.00 in cash, without interest, which is approximately 20% less than the price applicable to the Offer (such amendment, the “Warrant Amendment”). Pursuant to the terms of the Warrant Agreement, the adoption of the Warrant Amendment required the consent of holders of at least 50.1% of the then outstanding Warrants.

As of the Expiration Date, parties representing holders of approximately 9.1% of the outstanding Warrants consented to the Warrant Amendment in the Consent Solicitation. Accordingly, because holders of less than 50.1% of the outstanding Warrants agreed to consent to the Warrant Amendment in the Consent Solicitation, the Warrant Amendment was not approved.

The Offer and Consent Solicitation were made pursuant to an Offer to Purchase, initially dated August 27, 2024 (the “Offer to Purchase”), and a combined Tender Offer Statement and Rule 13e-3 Transaction Statement on Schedule TO (the “Schedule TO”), initially dated August 27, 2024, each as amended and supplemented from time to time, and each of which have been filed with the U.S. Securities and Exchange Commission (“SEC”) and more fully set forth in the terms and conditions of the Offer and Consent Solicitation. AvePoint will file a final amendment to its Schedule TO to disclose the final results of the Offer.